



INLAND EMPIRE HEALTH PLAN

# PHARMACY TIMES

BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT

December 3, 2010

## IEHP Pharmacy & Therapeutics Subcommittee Changes

We would like to inform you of the following changes to the 2010/2011 IEHP Formulary that were approved by the Pharmacy and Therapeutics Subcommittee in November 2010:

<b>Formulary Criteria Modification</b>			
<b>Drug Name</b>	<b>Classification</b>	<b>Medi-Cal/HF/HK</b>	<b>DualChoice</b>
Hyalgan (hyaluronic acid)	Viscous Supplement	Hyalgan and Euflexxa are both preferred hyaluronic acid supplement if criteria is met	Hyalgan and Euflexxa are both preferred hyaluronic acid supplement if criteria is met (a Part B covered drug)

## CLINICAL PRACTICE GUIDELINE UPDATE (AVAILABLE AT [WWW.IEHP.ORG](http://WWW.IEHP.ORG))

<b>Clinical Practice Guideline</b>	<b>Therapeutic Class Comment</b>
Depression	<b>Updated</b> Added Guidelines for Adolescent Depression in Primary Care Toolkit Added Major Depression in Adult in Primary Care Guide Added Practice Guideline For the Treatment of Patients with Major Depressive Disorder

GERD	No Change
Hyperlipidemia	No Change
Hypertension	No Change
Migraine	No Change
Multiple Sclerosis	No Change
Pulmonary Arterial Hypertension	No Change
Respiratory Syncytial Virus	No Change
Rheumatoid Arthritis	No Change
Smoking Cessation	No Change

### IMPORTANT INFORMATION ABOUT IEHP CLINICAL PRACTICE GUIDELINES

IEHP publishes and distributes an IEHP Formulary Book to our Providers every year. The IEHP Formulary Book contains IEHP treatment guidelines for drug therapy of various medical conditions and policies regarding the use of specific drugs. These recommendations (listed below), which have been approved by the Pharmacy and Therapeutics Subcommittee and Quality Management Committee, are based on published consensus guidelines and reviews of the medical literatures, they do not favor any particular drug based solely on cost considerations. All guidelines for therapy are current as of the time of printing and are subject to change. The Clinical Practice Guidelines are reviewed at least once every two years, or when a new update is available prior to the two-year schedule. When a new Clinical Practice Guideline is available, IEHP communicates the changes to the Provider via this quarterly Formulary Changes notice. The guidelines are general and may not cover all clinical situations; they should not be considered in any way as a substitute for sound clinical judgment.

IEHP Clinical Practice Guidelines currently available:

- Attention Deficit Hyperactivity Disorder Guideline and Toolkit
- Anti-Infective Therapy Guide Adult and Pediatric
- Asthma
- Depression MDD & Pediatrics
- Diabetes Mellitus & Diabetes Pregnancy
- Fibromyalgia
- Gastroesophageal Reflux Disease
- Hepatitis C
- Hyperlipidemia
- Hypertension
- Migraine
- Multiple Sclerosis
- Pulmonary Arterial Hypertension
- Pain Management
- Rheumatoid Arthritis

- Sexually Transmitted Diseases - Summary of CDC Treatment Guidelines
- Smoking Cessation
- Synagis Criteria Season 2010/2011

We welcome any recommendations and comments regarding the IEHP Formulary. For questions, suggestions, or if you would like a printed copy of the IEHP Formulary Book or Clinical Practice Guideline, please call us at (909) 890-2067. As a reminder, updated formulary information, drug criteria and Clinical Practice Guidelines are available at [www.iehp.org](http://www.iehp.org).

IEHP Pharmaceutical Services Department